Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UPQ4
UPID:
TRI35_HUMAN
Alternative names:
Hemopoietic lineage switch protein 5
Alternative UPACC:
Q9UPQ4; Q86XQ0; Q8WVA4
Background:
E3 ubiquitin-protein ligase TRIM35, also known as Hemopoietic lineage switch protein 5, plays a pivotal role in cell death, glucose metabolism, and the innate immune response. It is known for mediating 'Lys-63'-linked polyubiquitination of TRAF3, enhancing type I interferon production via the RIG-I signaling pathway. Additionally, TRIM35 can catalyze 'Lys-48'-linked polyubiquitination leading to the proteasomal degradation of viral proteins, such as the influenza virus PB2, and acts as a negative feedback regulator for TLR7- and TLR9-triggered signaling pathways.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase TRIM35 could open doors to potential therapeutic strategies, especially in enhancing antiviral responses and regulating immune signaling pathways.